Reference:
- C
Baigent, A
Keech, P
M
Kearney, and Cholesterol
Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of
cholesterol-lowering treatment: prospective meta-analysis of data from
90, 056 participants in 14 randomised trials of statins.Lancet . 2005; 366: 1267-78.
- Connie N Hess, Robert M Clare, Megan L Neely, et al. Differential
Occurrence, Profile, and Impact of First Recurrent Cardiovascular
Events After an Acute Coronary Syndrome. Am Heart J. 2017;187:
194-203.
- Jian-Jun
Li, Xin
Zheng, Jie
Li. Different Concept in Cholesterol Lower Therapy in Chinese
Atherosclerotic Cardiovascular Disease. Med
Hypotheses . 2007;69:333-7.
- Mei Zhang, Qian Deng, Linhong Wang, et al. Prevalence of Dyslipidemia
and Achievement of Low-Density Lipoprotein Cholesterol Targets in
Chinese Adults: A Nationally Representative Survey of 163,641 Adults.Int J Cardiol . 2018; 260:196-203.
- François
Mach, Colin
Baigent, Alberico L Catapano, et al. 2019 ESC/EAS Guidelines for the
Management of Dyslipidaemias: Lipid Modification to Reduce
Cardiovascular Risk. Eur Heart J . 2020; 41:111-188.
- Emelia
J
Benjamin, Salim
S
Virani, Clifton
W Callaway, et al. Heart Disease and Stroke Statistics-2018 Update: A
Report From the American Heart Association.Circulation . 2018;137:e67-e492.
- Li Y, Zhao SP, Ye P, et al. Status of Cholesterol Goal Attainment for
the Primary and Secondary Prevention of Atherosclerotic Cardiovascular
Disease in Dyslipidemia Patients Receiving Lipid-Lowering Therapy:
DYSIS-China Subgroup Analysis. Zhonghua Xin Xue Guan Bing Za
Zhi . 2016;44:665-70.
- Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability
of a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL):
a randomised, double-blind, placebo-controlled, phase 2 study.Lancet . 2012;380:1995–2006.
- Schwartz G G, Steg P G, Szarek M, et al. Alirocumab and Cardiovascular
Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;
379:2097-2107.
- Sabatine M S, Giugliano R P, Keech A C, et al. Evolocumab and Clinical
Outcomes in Patients with Cardiovascular Disease. N Engl J Med .
2017;376:1713-1722.
- Grundy SM, Stone NJ, Bailey AL, et al.
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on
the Management of Blood Cholesterol: A Report of the American College
of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. Circulation . 2019;139:e1082-e1143.
- Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of
myocardial infarction. J Am Coll Cardiol . 2012;60:1581–98.
- HPS2-THRIVE
randomized placebo-controlled trial in 25 673 high-risk patients of ER
niacin/laropiprant: trial design, pre-specified muscle and liver
outcomes, and reasons for stopping study treatment. Eur Heart
J . 2013;34:1279-1291.
- Atherosclerosis
and Coronary Heart Disease Working Group of Chinese Society of
Cardiology; Editorial
Board of Chinese Journal of CardiologyChinese Expert. Consensus on
Lipid Management of Very High-Risk Atherosclerotic Cardiovascular
Disease Patients. Zhonghua Xin Xue Guan Ji Bing Za Zhi .
2020;48:280-286.
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin
therapy after acute coronary syndromes. N Engl J Med. 2015;
372: 2387⁃2397.
- Koren MJ, Lundqvist P, Bolognese M, et al.
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2
randomized, controlled phase III clinical trial of evolocumab. J
Am Coll Cardiol . 2014;63:2531-2540.
- Drazen JM, Jarcho JA, Morrissey S, Curfman GD. Cholesterol Lowering
and Ezetimibe. N Engl J Med . 2008;358:1507-8.
- van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and
safety of coadministration of ezetimibe and simvastatin in adolescents
with heterozygous familial hypercholesterolemia. J Am Coll
Cardiol . 2008;52:1421-9.
- Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein
convertase neural apoptosisregulated convertase 1 (NARC-1): liver
regeneration and neuronal differentiation. Proc Natl Acad Sci
USA . 2003;100:928–933.
- Naureckiene S, Ma L, Sreekumar K, et al. Functional characterization
of Narc 1, a novel proteinase related to proteinase K. Arch
Biochem Biophys . 2003;420:55–67.
- Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its
natural mutants: zymogen cleavage and effects on the low density
lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem .
2004;279: 48865–48875.
- Cholesterol
Treatment Trialists’ (CTT)
Collaboration; C
Baigent, L
Blackwell, et al. Efficacy and Safety of More Intensive Lowering of
LDL Cholesterol: A Meta-Analysis of Data From 170,000 Participants in
26 Randomised Trials. Lancet . 2010;376:1670-81.